← Back to Search

Radiation Therapy

SABR for Lung Cancer (SUPPRESS-NSCLC Trial)

Phase 2
Recruiting
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Oligoprogression while on ICI or TKI (any line)
Metastatic NSCLC enrolled in our CRCHUM Lung Cancer Registry and co-enrolled to the PERa registry
Must not have
Presence of spinal cord compression Metastatic disease that invades the GI tract (including esophagus, stomach, small or large bowel)
Any lesion beyond 5 cm
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a new cancer treatment is better than the current standard of care.

Who is the study for?
This trial is for adults with metastatic non-small cell lung cancer who have limited progression in up to 5 body sites while on current cancer drugs. They must be able to consent, have a performance status of 0-3, and not be pregnant or breastfeeding. Lesions must be smaller than 5 cm and not involve the GI tract.
What is being tested?
The study compares standard care options versus adding stereotactic ablative radiotherapy (SABR) to existing systemic therapy for patients whose lung cancer has progressed but remains limited. Patients are randomly assigned to either continue/change their current treatment or receive SABR alongside it.
What are the potential side effects?
Potential side effects from SABR may include skin reactions, fatigue, shortness of breath, chest pain, and inflammation around treated areas. The severity can vary based on individual health conditions and previous treatments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer has spread in a limited way while on immunotherapy or targeted therapy.
Select...
I am registered in the CRCHUM Lung Cancer and PERa registries with metastatic NSCLC.
Select...
I am 18 years old or older.
Select...
I can care for myself but may not be able to do heavy physical work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My cancer has spread to my spine or digestive system.
Select...
I have a tumor larger than 5 cm.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
OS
PFS
Secondary study objectives
Grade ≥ 3 toxicity
Local control
Quality of life 5-level EQ-5D (EQ-5D-5L)
+2 more

Side effects data

From 2007 Phase 4 trial • 552 Patients • NCT00110890
7%
Diarrhoea
7%
Vomiting
3%
Nausea
3%
Nasopharyngitis
3%
Muscle spasms
1%
Angina pectoris
1%
Myocardial infarction
1%
Pericarditis
1%
Chest discomfort
1%
Hernia
1%
Jaundice
1%
Gastroenteritis
1%
Arteriovenous fistula thrombosis
1%
Joint dislocation
1%
Joint injury
1%
Shunt occlusion
1%
Shunt thrombosis
1%
Blood potassium increased
1%
Fluid retention
1%
Hypovolaemia
1%
Pancreatic carcinoma
1%
Cognitive disorder
1%
Skin ulcer
1%
Catheter placement
1%
Hypertensive crisis
1%
Arteriovenous fistula occlusion
1%
Orthostatic hypotension
1%
Cardiac arrest
1%
Chest pain
1%
Pyrexia
1%
Cholecystitis
1%
Arthritis bacterial
1%
Bacterial sepsis
1%
Fall
1%
Back pain
1%
Pain in extremity
1%
Dyspnoea
1%
Nephrectomy
1%
Hypotension
1%
Peripheral ischaemia
1%
Atrial flutter
1%
Cardiac asthma
1%
Abdominal pain
1%
Sudden cardiac death
1%
Transplant rejection
1%
Perianal abscess
1%
Pneumonia
1%
Urinary tract infection
1%
Ankle fracture
1%
Arteriovenous fistula site complication
1%
Rib fracture
1%
Cerebral infarction
1%
Gastrointestinal haemorrhage
1%
Catheter related infection
1%
Atrial fibrillation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Standard Care
Cinacalcet

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Experimental SABR armExperimental Treatment1 Intervention
Definitive SABR to oligoprogressive lesions + continue current systemic therapy
Group II: Standard of careActive Control1 Intervention
Switch to subsequent systemic therapy line, best supportive care or continue current systemic line

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
377 Previous Clinical Trials
131,312 Total Patients Enrolled
Houda Bahig, MD PhDStudy ChairCentre hospitalier de l'Université de Montréal (CHUM)
1 Previous Clinical Trials
106 Total Patients Enrolled
Bertrand Routy, MD PhDStudy ChairCentre hospitalier de l'Université de Montréal (CHUM)

Media Library

SABR (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04405401 — Phase 2
Lung Cancer Research Study Groups: Standard of care, Experimental SABR arm
Lung Cancer Clinical Trial 2023: SABR Highlights & Side Effects. Trial Name: NCT04405401 — Phase 2
SABR (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04405401 — Phase 2
~9 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top